Cristiane Dos Santos Dias

Prof. Dr. Cristiane Dos Santos Dias

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
FFFlávio de Azevedo Figueiredo
Flávio de Azevedo Figueiredo
LRLucas Emanuel Ferreira Ramos
Lucas Emanuel Ferreira Ramos
RSRafael Tavares Silva
Rafael Tavares Silva
DPDaniela Ponce
Daniela Ponce
RCRafael Lima Rodrigues Carvalho
Rafael Lima Rodrigues Carvalho
MMMilena Soriano Marcolino
Milena Soriano Marcolino
Background: Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. Methods: This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: The median age of the model-derivation cohort was 59 (IQR 47–70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918–0.939) and validation (temporal AUROC 0.927, 95% CI 0.911–0.941; geographic AUROC 0.819, 95% CI 0.792–0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator (https://www.mmcdscore.com/). Conclusions: The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.

11 October 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
DJDavi dos Reis de Jesus
Davi dos Reis de Jesus
AJAntônio Pereira de Souza Júnior
Antônio Pereira de Souza Júnior
EAElisa Tuler de Albergaria
Elisa Tuler de Albergaria
APAdriana Silvina Pagano
Adriana Silvina Pagano
IOIsaias Jose Ramos de Oliveira
Isaias Jose Ramos de Oliveira
ZRZilma Reis
Zilma Reis
Prescription systems support medication treatment by standardizing content, enhancing legibility and promoting correct dispensation. Challenges remain to personalize use instructions with sufficient clarity to meet patients' needs. Large Language Models (LLMs) are promising to improve communication in healthcare. This study investigates LLM Retrieval-Augmented Generation (RAG) drawing on patient information leaflets (PIL). We used a database with 119 outpatient scenarios to prepare prescriptions as input to LLMs. We evaluated patient instructions generated by open-source Llama3, using a standard prompt - model1, enhanced prompts with structured guidance - model2, and RAG-enhanced prompts incorporating PIL information from the Brazilian Health Regulatory Agency - model3. Five physicians independently scored the model-generated instructions, assessing adequacy, clarity, personalization and quality compared to reference texts; they reported their confidence level to perform the evaluation. Cosine similarity was computed between model-generated and reference texts. RAG introduction significantly improved instructions adequacy: median (interquartile range) 93.0 (40.0) vs. 94 (53.3) vs 100 (15.0), p = 0.001, and clarity 90.0 (60.0) vs. 92 (55.0) vs 95.0 (24.0), p = 0.012, for model1, model2, and model3 respectively. Enhanced prompt plus RAG in PIL reduced critical errors such as incorrect and incomplete instructions and factual inaccuracies. Prompt engineering positively impacted output, precluding the generation of vague and unsolicited instructions. Little impact of hallucination was found. Our findings underscore the role of AI in promoting safer medication use by incorporating authoritative medication information while maintaining concise and patient-friendly language. Human validation of output ensures error-free and safe implementation.

26 May 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ZRZilma Reis
Zilma Reis
EAElisa Tuler Albergaria
Elisa Tuler Albergaria
APAdriana Silvina Pagano
Adriana Silvina Pagano
ELEura Martins Lage
Eura Martins Lage
FOFlávia Ribeiro de Oliveira
Flávia Ribeiro de Oliveira
LRLeonardo Rocha
Leonardo Rocha
Background: The application of generative artificial intelligence to simplify medication use instructions has the potential to enhance people’s health by improving treatment adherence. Objective: We evaluated the performance of large language models (LLMs) in generating medication usage instructions to complement prescriptions in primary health care. Methods: This randomized, blinded experimental preclinical study used prescription-inducing scenarios, assigned to 62 health care professionals, to validate instructions generated by LLMs during electronic prescriptions. The instructions were generated by ChatGPT-4.0 (OpenAI), Llama3.1-8B (Meta), and Llama3.1-8B-RAG (Meta) using retrieval-augmented generation based on patient information leaflets. Performance metrics assessed adequacy, completeness, clarity, language simplification, usefulness, and errors in the generated instructions, with scores to analyze overall and individual metrics. Results: The 3 models yielded high overall scores for producing qualified instructions (ChatGPT-4.0: median 88.4, IQR 22.8; Llama3.1-8B: median 66.5, IQR 50.9; Llama3.1-8B-RAG: median 79.9, IQR 34.4; Kruskal-Wallis test P=.003). Llama3.1-8B-RAG received evaluations with similar overall scores to ChatGPT-4.0 (post hoc test, P=.05) and similar to Llama3.1-8B (post hoc test, P=.44). ChatGPT-4.0 outperformed Llama3.1-8B (Bonferroni test, P<.001). Regarding specific domains, Llama3.1-8B-RAG received scores equivalent to those of ChatGPT-4.0 for adequacy (mean 6.24, SD 2.3 vs mean 6.82, SD 2.1; post hoc test, P=.54); completeness (mean 5.94, SD 2.2 vs 6.55, SD 1.9; post hoc test P=.38), clarity (mean 5.77, SD 2.4 vs mean 6.68, SD 1.9; post hoc test P=.09), and usefulness (mean 5.42, SD 2.4 vs mean 5.96, SD 2.2; post hoc test P=.63). ChatGPT-4.0 received higher scores in the language simplification criterion than Llama3.1-8B-RAG (mean 7.05, SD 1.5 vs mean 5.44, SD 2.6; post hoc test P<.001). Interrater variability in assigning scores ranged from 4.2% (n=3) to 85.8% (n=6) among primary health care professionals. Instructions leading to incorrect use of the medication had similar frequency among the models(ChatGPT-4.0: n=15, 22.7%; Llama3.1-8B: n=19, 22.8%; Llama3.1-8B-RAG: n=19, 22.8%; chi-square test P=.71). The frequencies of hallucination were similar (ChatGPT-4.0: n=7, 10.6%; Llama3.1-8B: n=9, 13.6%; Llama3.1-8B-RAG: n=6, 9.1%; chi-square test P=.67). Conclusions: The open-source LLM enhanced with external information presented similar performance to the closed-source model, except for ChatGPT4.0, which was superior in language simplification of messages. LLM generation demonstrated potential for instructing patients on medication use. Nonetheless, the introduction of this innovation into the electronic prescribing workflow demands prescriber validation for human oversight of the technology and requires a strategy for LLM performance governance. International Registered Report Identifier (IRRID): RR2-10.12688/verixiv.1359.1

14 April 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
EOEduardo Oliveira
Eduardo Oliveira
MOMARIA CHRISTINA Christina lopes Araújo OLIVEIRA
MARIA CHRISTINA Christina lopes Araújo OLIVEIRA
HMHercilio Martelli-Junior
Hercilio Martelli-Junior
FOFabrício Emanuel Soares de Oliveira
Fabrício Emanuel Soares de Oliveira
DMDaniella Reis Barbosa Martelli
Daniella Reis Barbosa Martelli
ECEnrico Antonio Colosimo
Enrico Antonio Colosimo
In the SARS-CoV-2 endemic phase, assessing the effectiveness of COVID-19 booster doses in children is essential for public health policy. This study evaluated the vaccine effectiveness (VE) of three doses (primary series plus booster) against severe outcomes, comparing the pandemic and endemic periods and children with and without comorbidities. We carried out a cohort study based on the population, utilizing comprehensive Brazilian data from individuals under 18 years of age with confirmed SARS-CoV-2 infection, spanning from February 2020 to June 2025. The primary exposure of interest was three or more doses of COVID-19 vaccines. The primary outcome of interest was COVID-19-related death. VE and the number needed to vaccinate (NNV) to prevent one death were estimated in a propensity score-matched cohort, with adjustments for confounders. Among 3,730,007 reported pediatric cases, 5472 (0.1%) died, 99% of whom did not receive a booster dose. During the pandemic, the VE against death was higher in children with comorbidities (92.7% [95% CI, 63.5–99.0]; NNV = 23 [19–30]) than in those without (68.2% [25.7–86.4]; NNV = 2000 [1111–9774]). During the endemic period, the VE against death remained high and was comparable between groups: 89.4% (29.8–98.7) and 75.8% (36.4–95.7) for children with and without comorbidities, respectively. Nevertheless, NNV levels were significantly lower in children with comorbidities, reflecting an increased risk at baseline. Although booster doses continue to offer substantial protection against fatal COVID-19 outcomes, the magnitude of this benefit is directly correlated with the baseline risk. Consequently, these findings support the implementation of risk-based prioritization strategies in public health decision-making for children.

24 April 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
MOMARIA CHRISTINA Christina lopes Araújo OLIVEIRA
MARIA CHRISTINA Christina lopes Araújo OLIVEIRA
DMDaniella Reis Barbosa Martelli
Daniella Reis Barbosa Martelli
ASAna Cristina Simões e Silva
Ana Cristina Simões e Silva
CDCristiane Dos Santos Dias
Cristiane Dos Santos Dias
DODiniz Lílian Martins Oliveira
Diniz Lílian Martins Oliveira
EOEduardo Oliveira
Eduardo Oliveira
To investigate the real-world effectiveness of COVID-19 vaccines in a large cohort of patients with diabetes mellitus (DM), we analyzed all >18-year-old patients with COVID-19 registered in a Brazilian nationwide surveillance database between February 2020 and February 2023. The primary outcome of interest was vaccine effectiveness against death, evaluated using multivariate logistic regression models. Among the 2,131,089 patients registered in the SIVEP-Gripe, 482,677 (22.6%) had DM. After adjusting for covariates, patients with DM had a higher risk of death than those without comorbidities (adjusted odds ratio [aOR] = 1.43, 95% CI, 1.39–1.47). For patients without comorbidities (72.7%, 95% CI, 70.5–74.7) and those with DM (73.4%, 95% CI, 68.2–76.7), vaccine effectiveness was similar after the booster dose. However, it was reduced in patients with DM associated with other comorbidities (60.5%; 95% CI, 57.5–63.2). The strongest factor associated with booster failure was the omicron variant (aOR = 27.8, 95% CI, 19.9–40.1). Our study revealed that COVID-19 vaccines provided robust protection against death in individuals with DM. However, our findings underscore the need to update vaccines and develop tailored strategies for individuals with diabetes, especially those with additional underlying conditions.

20 February 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
LCLaura Coelho
Laura Coelho
DODiniz Lílian Martins Oliveira
Diniz Lílian Martins Oliveira
SGStella Galante
Stella Galante
CDCristiane Dos Santos Dias
Cristiane Dos Santos Dias
MOMARIA CHRISTINA Christina lopes Araújo OLIVEIRA
MARIA CHRISTINA Christina lopes Araújo OLIVEIRA
EOEduardo Oliveira
Eduardo Oliveira
Pediatric patients with SARS-CoV-2 infection are at an increased risk of severe disease and adverse outcomes. Nevertheless, comprehensive data on COVID-19 vaccine effectiveness (VE) in children with diabetes during the post-pandemic period remain limited. This study assessed the VE against severe COVID-19 outcomes during both the pandemic and post-pandemic phases in children with and without diabetes mellitus (DM). A cohort study based on population data was carried out, including all patients under 18 years of age with symptomatic SARS-CoV-2 infection as registered in the Brazilian national surveillance systems from February 2020 to June 2025. The main outcomes were hospitalization due to COVID-19 and severe illness, which included admission to the intensive care unit (ICU), need for invasive ventilation, and death. Utilizing a propensity score-matched cohort, we estimated the VE and the number needed to vaccinate (NNV) for a booster dose against these outcomes by comparing vaccinated and unvaccinated individuals, employing conditional logistic regression adjusted for confounding variables. The cohort comprised 3,730,007 pediatric patients with COVID-19, of whom 7675 (0.2%) had DM. At baseline, children with DM exhibited a significantly higher prevalence of hospitalization (11.2% vs. 2.0%), severe COVID-19 (6.4% vs. 0.6%), and mortality (1.9% vs. 0.1%) than those without DM (all p < 0.001). During the pandemic period, the adjusted VE was consistently higher in children with DM. Against severe disease, the VE was 72.8% (95% CI: 12.3–93.2) in the DM cohort compared with 45.7% (28.1–59.0) in the non-DM cohort. This increased effectiveness corresponded to a more favorable NNV; the NNV to prevent one severe case was 24 (95% CI: 12–232) for children with DM versus 243 (168–440) for those without DM. In the post-pandemic period, the VE remained significantly higher in the DM cohort. Against severe disease, the VE was 76.2% (11.5–93.5) for children with DM and 52.9% (32.7–67.1) for those without. The NNV to prevent one severe case was consistently lower in the DM cohort (8 vs. 591). In conclusion, a complete vaccination regimen, including a booster dose, substantially mitigated severe COVID-19 outcomes in children with DM in the pandemic and post-pandemic periods.